


biotechne®

Redefining Industry Standards

WITH NEXT GENERATION **Flt-3 Ligand**



Renowned R&D Systems™ quality with Bio-Techne Innovation

For almost 40 years, R&D Systems™, a Bio-Techne brand, has strived to offer high quality proteins to enable your scientific research. Over the years, we continuously improve by incorporating scientific advancements in protein purification and cell culture.

Rather than just meeting industry standards, we're on a mission to define them. Our modernized methods safeguard your access to high-quality recombinant proteins throughout your research journey.

Our **next generation** of cytokines and growth factors merges our renowned quality and innovation, offering you an unparalleled combination of dependability and stability of supply. These best-in-class proteins ensure your research remains at the forefront of progress. Consider our **Next Generation Flt-3 Ligand** ([Catalog # BT-FT3L](#)) and explore the key benefits!

Key Benefits of Our Next Generation Flt-3 Ligand Protein



Increased Supply: Improved manufacturing processes allow for greater scalability & robust supply chain.



Same Source: Our legacy and next generation proteins are derived from the *same E. coli* expression system.




Time & Cost-Savings: Cost-effective proteins with larger lot sizes, allowing for less time spent on bridging studies



Equivalent Bioactivity: Our next generation Flt-3 Ligand protein displays the same activity as our legacy protein.

[Learn more | bio-techne.com/proteins/reagents/nextgenerationproteins](https://www.bio-techne.com/proteins/reagents/nextgenerationproteins)

Figure 1: Analysis of Next Generation Flt-3 Ligand Protein Bioactivity



New Recombinant Human Flt-3 Ligand Protein Activity.

Comparison of new ([Catalog # BT-BT3L](#)) and legacy ([Catalog # 308-FKE](#)) *E. coli*-derived Recombinant Human Flt-3LG as measured in a cell proliferation assay using the cell proliferation of OCI-AML5 acute myeloid leukemia cells. Both proteins display similar activity.

Table: Comparison of Legacy and Next Generation Recombinant Human Flt-3 Ligand Proteins

Specifications	308 FKE (Legacy)	BT FT3L (Next Generation)
Activity	Measured in a cell proliferation assay using BaF3 mouse pro-B cells transfected with mouse Flt-3. The ED ₅₀ for this effect is 0.2-1 ng/mL.	Measured in a cell proliferation assay using OCI-AML5 acute myeloid leukemia cells. The ED ₅₀ for this effect is 0.2-2 ng/mL.
Source	<i>E. coli</i> -derived human Flt-3 Ligand/FLT3L protein Thr27-Ala181	<i>E. coli</i> -derived human Flt-3 Ligand/FLT3L protein Thr27-Ala181
Purity	>95%, by SDS-PAGE	>97%, by SDS-PAGE
N-terminal Sequence	Met and Thr27	Met & Thr27
Predicted Molecular Mass	18 kDa	18 kDa
Pack Sizes	10, 50, 100, 250 µg, 1 mg	10, 50, 100, 250 µg, 1 mg
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS.	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.
Endotoxin	<0.10 EU per 1 µg of the protein by the LAL method.	<0.10 EU per 1 µg of the protein by the LAL method.